Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies

Antimalarial chemotherapy relies on combination therapies (ACTs) consisting of an artemisinin derivative and a partner drug. Here, the authors study the effects of globally prevalent mutations in a multidrug resistance transporter (PfMDR1) on the parasite’s susceptibility to ACT drugs.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: M. Isabel Veiga, Satish K. Dhingra, Philipp P. Henrich, Judith Straimer, Nina Gnädig, Anne-Catrin Uhlemann, Rowena E. Martin, Adele M. Lehane, David A. Fidock
Format: article
Langue:EN
Publié: Nature Portfolio 2016
Sujets:
Q
Accès en ligne:https://doaj.org/article/dbb046e77b4e470caabc3ad9b066a983
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Antimalarial chemotherapy relies on combination therapies (ACTs) consisting of an artemisinin derivative and a partner drug. Here, the authors study the effects of globally prevalent mutations in a multidrug resistance transporter (PfMDR1) on the parasite’s susceptibility to ACT drugs.